iPad Extra: Next Steps for Sorafenib in RAI-Refractory DTCOncology Times: 25 September 2013 - Volume 35 - Issue 18 - p 5 doi: 10.1097/01.COT.0000435377.89374.6f News Get the iPad edition of this issue to listen to additional key thyroid cancer news from the ASCO Annual Meeting. Download the Sept. 25 FOCUS: Thyroid Cancer Supplement iPad issue to hear OT reporter Dan Keller's video interview with: • Marcia S. Brose, MD, PhD, Assistant Professor of Otolaryngology and Head and Neck Surgery at Abramson Cancer Center and Perelman School of Medicine at the University of Pennsylvania, who discusses the results of the DECISION trial and the next steps of the research. The data, reported at the Plenary Session, showed that the multi-targeted drug sorafenib extends progression-free survival for patients with differentiated thyroid cancer that is resistant to standard radioiodine therapy—making it the first drug to demonstrate efficacy of any agent for this type of thyroid cancer. To receive our iPad issues, download the free Oncology Times app from the App Store from http://bit.ly/OT-iPadApp, search in the App Store, or follow the link on oncology-times.com. © 2013 by Lippincott Williams & Wilkins, Inc. Article Outline Source iPad Extra: Next Steps for Sorafenib in RAI-Refractory DTC Oncology Times. 35(18):5, September 25, 2013. Full-Size Email + Favorites Export View in Gallery Email to a Friend Friend's E-mail is Invalid Your Name: (optional) Your Email: Friend's Email: Separate multiple e-mails with a (;). Message: Thought you might appreciate this item(s) I saw at Oncology Times. Send a copy to your email Your message has been successfully sent to your friend. Some error has occurred while processing your request. Please try after some time. Add Item(s) to: An Existing Folder A New Folder Folder Name: Description: The item(s) has been successfully added to "". More on ONCOLOGY-TIMES.com... Home Clinical Resource Center Current Issue Search OT Archives Get OT Enews Blogs Email us!